Pazopanib in Relapsed and Refractory Small Cell Lung Cancer

NCT01713296 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

58

Enrollment

OTHER

Sponsor class

Conditions

SCLC

Interventions

DRUG: Pazopanib

Sponsor

Hellenic Oncology Research Group